Laura McAuliffe, PharmD, BCACP, CDE

Laura McAuliffe, PharmD, BCACP, CDCES

Senior Clinical Pharmacist Specialist, Ambulatory Care; Director, PGY2 Ambulatory Care Pharmacy Residency Program

Education: Doctor of Pharmacy, Massachusetts College of Pharmacy and Health Services, Worcester

Residencies: PGY1, Lahey Hospital and Medical Center; PGY2, Rhode Island Hospital - University of Rhode Island PGY2 Ambulatory Care Program

Practice/Research Interests: Direct patient care and medication management of ambulatory patients, pharmacy education, transitions of care

Select Publications: 

Riester M, McAuliffe L, Collins C, Zullo A. Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF), AJHP;2021;78(18):1691–1700.

Mogul A, Corsi, K and McAuliffe L. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. Annals of Pharmacotherapy. 2019.

McAuliffe [Hunt] L, Zullo AR, Dapaah-Afriyie R, and Berard-Collins, C. Development and validation of a transitions-of-care pharmacist tool to predict potentially avoidable 30-day readmissions. AJHP. 2018;75(3):111-19.